It's cleanroom panel with double-magnesium oxide board and rock wool is an ideal choice for a pharmaceutical factory
In late-stage clinical trials in Brazil, Sinovac Biotech's vaccine has shown 78% effectiveness in fighting COVID-19 and can prevent severe illness.
China Sinovac Biotech cooperated with Butanta Research Institute, Brazil's largest vaccine manufacturer, to conduct Phase III clinical research in Brazil.
The agency said on Thursday that among the volunteers vaccinated, there were no severe cases.
Although the effectiveness of Sinovac Biotech CoronaVac vaccine is not more than 90% like Moderna, this vaccine is easier to transport and can be stored at normal refrigerator temperature.
In December 2020, Sinovac Biotech announced that it is expected to produce 300 million doses of vaccine in 2020 and increase its production capacity to 600 million doses per year.
Sinovac Biotech has built a factory in Beijing to produce the COVID-19 vaccine.
At present, Sinovac Biotech's vaccine research and development laboratory in China is provided by Wiskind with cleanroom materials, using a total of 15,000 square meters of cleanroom panels.
In view of the particularity of the vaccine laboratory, and taking into account the strength and aesthetic performance of cleanroom panels, Wiskind provides cleanroom panel with double-magnesium oxide board and rock wool, which have the advantages of drug resistance, corrosion resistance and pollution resistance. It is an ideal choice for pharmaceutical factory.
As a professional cleanroom enclosure system service provider, Wiskind has the world’s first cleanroom panels production line with independent knowledge products, which can produce a variety of core materials and can be customised to meet the needs of different industries.
Used in pharmaceuticals, food, electronics and hospitals, Whisking provide professional cleanroom panels and technical support services for hundreds of customers in many fields.